A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
about
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaTargeting acute myeloid leukemia with TP53-independent vosaroxin.Emerging therapies for acute myeloid leukemia.Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemiaA "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.Therapies for acute myeloid leukemia: vosaroxin.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Emerging strategies for the treatment of older patients with acute myeloid leukemia.The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
P2860
Q28072058-1DD08755-9255-4B6A-81FA-75D7017A9AE4Q30245472-F0DDF504-8570-45EB-94D9-DD3657BDF539Q33576363-BBA2B4F4-7CC4-4F75-97B8-96DF3C657881Q33728180-7B0C705F-785D-493A-BB84-0766B9FFEF33Q35546759-9122286A-E553-46A6-AC92-599A00621B15Q36053792-7CD0CA6B-A55F-4146-BEE7-2DE7CCF10875Q36770191-CB5F6F3D-F9D0-4E47-B7B4-641DF33545A8Q36881957-76247082-E153-4D8D-AB86-C0BF0EB9F0B1Q37204002-86698F1A-13FF-42C1-AF55-81DEEE6E55CAQ38469793-422534D2-CDB4-4B9F-A5ED-A7C75D4A92DFQ38598953-A04BB4F4-67A5-492E-B9E7-8AE66410094CQ38644941-50745AEC-EA41-428A-8D5E-4CF58F6B0ABCQ38664735-267238B3-AEAE-4C3E-B393-90C5A651BD96Q38818726-14B6579B-08B3-448D-9262-BA44F9AD3A37Q38829544-718CC3BD-48C4-4744-B488-8948C9B142C9Q39175665-BF031F37-842B-4DFC-80D6-8F65E79D12F9Q39306416-B51A2DCE-F2B9-4E22-8145-59FB5B2CCC85Q39342733-A3F134FA-C997-4F91-92A5-4A4AD5C4D16CQ46425542-A487FAD1-C6A3-43BB-8051-EA67667E9927
P2860
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@ast
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@en
type
label
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@ast
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@en
prefLabel
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@ast
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@en
P2093
P2860
P1433
P1476
A phase 1b/2 study of vosaroxi ...... ractory acute myeloid leukemia
@en
P2093
Adam R Craig
Gail J Roboz
Glenn C Michelson
Jeffrey E Lancet
Judith A Fox
Judith E Karp
Larry D Cripe
Michael B Maris
Rachael Hawtin
Richard D Leavitt
P2860
P304
P356
10.3324/HAEMATOL.2014.114769
P577
2014-11-07T00:00:00Z